Gambro buys back Korean selling rights:
This article was originally published in Clinica
Gambro, the Swedish-based renal care company, has acquired the sales rights in Korea for certain products from its COBE subsidiary, representing annual sales of $6 million. Seajin Medicare, which has 10 employees, will fold itself into Gambro Korea and its president, KS Chai, will become president of Gambro Korea. He succeeds Bo-Inge Hansson, who moves up to become president, Gambro Asia Pacific. The items concerned include COBE BCT blood component technology and renal care products.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.